US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Amplify EASI Tactical Growth ETF

21.07

0.0000

Volume:- -

Turnover:- -

Market Cap:10.54M

PE:- -

High:21.07

Open:21.07

Low:21.07

Close:21.07

52wk High:28.51

52wk Low:18.71

Shares:500.00K

Float Shares:500.00K

Volume Ratio:- -

T/O Rate:- -

Dividend:- -

Dividend Rate:- -

ROE:--

ROA:--

PB:--

PE(LYR):- -

Loading ...

Overview Company News Filings

Concept

no data

No relevant data is available

Capital Flow

Inflow:

Outflow:

News

Study Results of Novel TYK2 Inhibitor Soficitinib in Patients with AD Published by JAMA Dermatology

Kymera Therapeutics Outlines Key 2026 Objectives and Strategy to Advance Industry Leading Portfolio of Oral Immunology Programs

Nektar Alopecia Trial Misses Endpoint, Hits Significance After Patient Exclusion

Benzinga_recent_news

United Laboratories Unit Reports Positive Phase 2 Results for Atopic Dermatitis Drug; Shares Gain 3%

MT Newswires Live

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/EASI"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"EASI","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"EASI\",,,,,undefined,":{"symbol":"EASI","market":"US","secType":"STK","nameCN":"Amplify EASI Tactical Growth ETF","latestPrice":21.07,"timestamp":1593720000000,"preClose":21.07,"halted":4,"volume":0,"delay":0,"changeRate":0,"floatShares":500000,"shares":500000,"eps":0,"marketStatus":"Delisted","change":0,"latestTime":"07-02 16:00:00 EDT","open":21.07,"high":21.07,"low":21.07,"amount":0,"amplitude":0,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":1,"ttmEps":0,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1770627600000},"marketStatusCode":7,"adr":0,"adrRate":0,"exchange":"ARCA","adjPreClose":21.07,"sharesOutstanding":500000,"nav":21.1,"aum":0,"bidAskSpread":0,"volumeRatio":0},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"EASI\",,,,,undefined,":{"symbol":"EASI","floatShares":500000,"roa":"--","roe":"--","lyrEps":0,"shares":500000,"dividePrice":0,"high":21.07,"amplitude":0,"preClose":21.07,"low":21.07,"week52Low":18.71,"pbRate":"--","week52High":28.5068,"institutionHeld":0,"latestPrice":21.07,"eps":0,"divideRate":0,"volume":0,"delay":0,"ttmEps":0,"open":21.07},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/EASI\",params:#limit:5,,,undefined,":[{"market":"US","date":"2019-12-30","symbol":"EASI","amount":0.0709424,"name":"Amplify EASI Tactical Growth ETF","payableDate":"2019-12-31","currency":"USD","type":"dividend","dateTimestamp":1577682000000},{"market":"US","date":"2019-06-27","symbol":"EASI","amount":0.1005274,"name":"Amplify EASI Tactical Growth ETF","payableDate":"2019-06-28","currency":"USD","type":"dividend","dateTimestamp":1561608000000},{"market":"US","date":"2018-12-28","symbol":"EASI","amount":0.0997123,"name":"Amplify EASI Tactical Growth ETF","currency":"USD","type":"dividend","dateTimestamp":1545973200000}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"EASI\",market:\"US\",,,undefined,":[{"executeDate":"2018-12-28","recordDate":null,"paymentDate":null,"value":0.0997123,"currency":"USD"},{"executeDate":"2019-06-27","recordDate":"2019-06-28","paymentDate":null,"value":0.1005274,"currency":"USD"},{"executeDate":"2019-12-30","recordDate":"2019-12-31","paymentDate":null,"value":0.0709424,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"EASI\",market:\"US\",delay:true,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"EASI\",pageSize:4,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2607018517","title":"Study Results of Novel TYK2 Inhibitor Soficitinib in Patients with AD Published by JAMA Dermatology","url":"https://stock-news.laohu8.com/highlight/detail?id=2607018517","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2607018517?lang=en_us&edition=fundamental","pubTime":"2026-01-29 16:17","pubTimestamp":1769674620,"startTime":"0","endTime":"0","summary":"BEIJING, Jan.  29, 2026  (GLOBE NEWSWIRE) -- JAMA Dermatology recently published the results of a Phase II study of novel TYK2 inhibitor soficitinib (ICP-332) in patients with moderate-to-severe atopi","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/01/29/3228229/0/en/Study-Results-of-Novel-TYK2-Inhibitor-Soficitinib-in-Patients-with-AD-Published-by-JAMA-Dermatology.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AMA","BK4132","AD","EASI"],"gpt_icon":0},{"id":"2603686974","title":"Kymera Therapeutics Outlines Key 2026 Objectives and Strategy to Advance Industry Leading Portfolio of Oral Immunology Programs","url":"https://stock-news.laohu8.com/highlight/detail?id=2603686974","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2603686974?lang=en_us&edition=fundamental","pubTime":"2026-01-13 20:00","pubTimestamp":1768305600,"startTime":"0","endTime":"0","summary":"KT-621 BROADEN2 Phase 2b trial in AD ongoing, with data expected by mid-2027 KT-621 BREADTH Phase 2b trial in asthma initiated, with data expected in late-2027  KT-579 Phase 1 HV clinical trial expect","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/01/13/3217633/0/en/Kymera-Therapeutics-Outlines-Key-2026-Objectives-and-Strategy-to-Advance-Industry-Leading-Portfolio-of-Oral-Immunology-Programs.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["KYMR","BP","BK4096","AD","LU1829250122.USD","BK4139","EASI","LU0162691827.USD","LU0320765646.SGD","IBD","PN","RA","LU1162221912.USD","BK4201","BK4585","LU0072461881.USD","BK4132","BK4588"],"gpt_icon":0},{"id":"2592399309","title":"Nektar Alopecia Trial Misses Endpoint, Hits Significance After Patient Exclusion","url":"https://stock-news.laohu8.com/highlight/detail?id=2592399309","media":"Benzinga_recent_news","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2592399309?lang=en_us&edition=fundamental","pubTime":"2025-12-17 00:30","pubTimestamp":1765902600,"startTime":"0","endTime":"0","summary":"Nektar Therapeutics reported Phase 2b alopecia areata data showing hair regrowth trends, narrowly missing significance before eligibility adjustments.","market":"hk","thumbnail":"https://cdn.benzinga.com/files/images/story/2025/12/16/Nov-2--2019-San-Francisco-----Ca-----Usa.jpeg?optimize=medium&dpr=2&auto=webp&width=240","type":0,"news_type":0,"thumbnails":["https://cdn.benzinga.com/files/images/story/2025/12/16/Nov-2--2019-San-Francisco-----Ca-----Usa.jpeg?optimize=medium&dpr=2&auto=webp&width=240"],"rights":{"source":"benzinga_recent_news","url":"https://www.benzinga.com/markets/biotech/25/12/49426419/nektar-alopecia-trial-misses-endpoint-hits-significance-after-patient-exclusion","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/markets/biotech/25/12/49426419/nektar-alopecia-trial-misses-endpoint-hits-significance-after-patient-exclusion","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"benzinga_recent_news","symbols":["EASI","BSA","BK4007","NKTR"],"gpt_icon":0},{"id":"2582338187","title":"United Laboratories Unit Reports Positive Phase 2 Results for Atopic Dermatitis Drug; Shares Gain 3%","url":"https://stock-news.laohu8.com/highlight/detail?id=2582338187","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582338187?lang=en_us&edition=fundamental","pubTime":"2025-11-11 10:17","pubTimestamp":1762827460,"startTime":"0","endTime":"0","summary":"United Laboratories International  said its wholly owned unit, Zhuhai United Laboratories, has completed a Phase 2 clinical trial in China for TUL01101 tablets, a Class 1 new drug for treating moderate-to-severe atopic dermatitis, according to a Monday bourse filing.Shares of the firm were up nearly 3% in Tuesday morning trade.The multicenter trial enrolled 201 adult patients and tested three dose groups over 12 weeks.All doses showed significant efficacy, with Eczema Area and Severity Index  score reductions of up to 87.9% and an EASI-75 response rate as high as 84%, according to the filing.The drug also demonstrated a favorable safety profile, with most adverse events being mild to moderate.Following the positive results, the company has begun discussions with regulators and is initiating a Phase 3 clinical trial in China.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["UBCP","BK1191","BK4211","03933","EASI"],"gpt_icon":0}],"pageSize":4,"totalPage":2,"pageCount":1,"totalSize":7,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/market/plate/belongs/EASI\",params:#limit:6,delay:true,,,undefined,":[]}}